Update date
01 Jul 2026
China SXT Pharmaceuticals, Inc. financial metrics
Period Q1 2026 · Filed 01 Jul 2026
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
958,077
Period-end balance · 31 Mar 2026
|
|
| Common Stock, Value, Issued |
$64,125,702
Period-end balance · 31 Mar 2026
|
+44% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$497,648
Period-end balance · 31 Mar 2026
|
-57% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$931,567
Period-end balance · 31 Mar 2026
|
-28% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
-$197,878
Period-end balance · 31 Mar 2026
|
+82% |
| Assets |
$34,754,574
Period-end balance · 31 Mar 2026
|
+60% |
| Assets, Current |
$34,509,722
Period-end balance · 31 Mar 2026
|
+62% |
| Cash and Cash Equivalents, at Carrying Value |
$28,175,865
Period-end balance · 31 Mar 2026
|
+56% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$28,176,233
Period-end balance · 31 Mar 2026
|
+55% |
| Contract with Customer, Liability, Current |
$104,423
Period-end balance · 31 Mar 2026
|
+78% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$1,077,219
Period-end balance · 31 Mar 2026
|
+20% |
| Deferred Tax Assets, Valuation Allowance |
$1,715,292
Period-end balance · 31 Mar 2026
|
+19% |
| Intangible Assets, Net (Excluding Goodwill) |
$6,328
Period-end balance · 31 Mar 2026
|
-46% |
| Inventory, Net |
$777,059
Period-end balance · 31 Mar 2026
|
-6.2% |
| Liabilities |
$5,047,152
Period-end balance · 31 Mar 2026
|
-19% |
| Liabilities and Equity |
$34,754,574
Period-end balance · 31 Mar 2026
|
+60% |
| Liabilities, Current |
$4,349,320
Period-end balance · 31 Mar 2026
|
-28% |
| Operating Lease, Liability |
$121,421
Period-end balance · 31 Mar 2026
|
-31% |
| Operating Lease, Right-of-Use Asset |
$121,421
Period-end balance · 31 Mar 2026
|
-31% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.054
Period-end balance · 31 Mar 2026
|
0% |
| Property, Plant and Equipment, Gross |
$2,738,432
Period-end balance · 31 Mar 2026
|
+5.2% |
| Property, Plant and Equipment, Net |
$117,103
Period-end balance · 31 Mar 2026
|
-34% |
| Retained Earnings (Accumulated Deficit) |
-$34,220,402
Period-end balance · 31 Mar 2026
|
-22% |
| Stockholders' Equity Attributable to Parent |
$29,707,422
Period-end balance · 31 Mar 2026
|
+92% |
Comparisons, sources and research notes
Sources and sharing
SXTC - China SXT Pharmaceuticals, Inc. Financial Facts
- Context
- Latest metrics period: Q1 2026
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2026.
- Most recent SEC facts end date on this page: 31 Mar 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for SXTC - China SXT Pharmaceuticals, Inc.
Latest financial period: Q1 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 01 Jul 2026.
Filing notes and source
Key facts
- SXTC - China SXT Pharmaceuticals, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q1 2026.
- Headline metric summary will appear when SEC facts are available.
Change
- No metrics are currently available for comparison on this facts page.
- Changes will populate automatically as new 10-Q/10-K periods are processed.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -4,017,456.0 USD · through 2026-03-31 · reported annual SEC source
- Capital expenditures: 2,023.0 USD · through 2025-03-31 · reported annual SEC source
- Cash and equivalents: 28,175,865.0 USD · through 2026-03-31 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Valuation unavailable: free cash flow is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
n/a
Insufficient Data Confidence low
Financial Health
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first